Hospital Británico de Buenos Aires - CABA
Desde el año 2000, el Centro de Oncología del Hospital Británico de Buenos Aires es un espacio que combina calidad asistencial en oncología con una visión centrada en el paciente y en la innovación a través de la investigación clínica. Nuestra misión y visión nos impulsa a la mejora continua participando en el desarrollo y aplicación de nuevos tratamientos para los pacientes con diagnóstico de cáncer en nuestro país.Perdriel 74, CABA, Buenos Aires
Select an option
I am a doctor
I am a sponsor
Specializations
Cáncer de mama
Cáncer de pulmón
Cáncer de próstata
Cáncer de vejiga
Cáncer de riñón
Cáncer
Tumores sólidos Cáncer
Enfermedad de Crohn
Bacteriemia por estafilococo aureus Bacteriemia
Leucemia
Colitis ulcerosa
Hipertensión pulmonar
Pan Tumor Cáncer
Hipertensión arterial pulmonar
Melanoma
Enfermedad de Huntington
Artroplastia Reemplazo de rodilla
Miocardiopatía
Nefropatía Enfermedad renal
Enfermedad renal crónica Anemia
Carcinoma hepatocelular Cáncer de hígado
Nefropatía
Colangitis biliar primaria
Our team
Medical staff
Agustín Miguez
Belén Virasoro
Silvina Palmer
Karina Vera
Natalia Roldan
Micalea Conde
Anahí Martinez
María Acevedo
Anahi Martinez
Ernesto Korbenfeld
Luciana Bella Quero
Yamila Chichotky
Maximiliano Romero
Karina Alejandra Vera
Cintia Novas
Luis Colombato
Patricia Delgado
Hernán Trimarchi
Juan Andres de Paula
Nora Fernández
Javier Benavides
Patricia Delgado
Mariana Lopez
Hugo Armando Laborde
Macarena Saenz
Maria Victoria Dolores Mujica
Claudia M. Shanley
Open studies
Lung cancer
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) - B-FAST - Hoffmann-La RocheSee more
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - AbbVieSee more
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation - Krascendo 170 - Hoffmann-La RocheSee more
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) - TRIDENT-3 - Zai Lab (Shanghai) Co., Ltd.See more
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) - CodeBreaK 202 - AmgenSee more
A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy - SKYSCRAPER-15 - Hoffmann-La RocheSee more
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) - MK 2870-007 - Merck Sharp & Dohme LLCSee more
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) and Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) - Merck Sharp & Dohme LLCSee more
Breast Cancer
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) - VIKTORIA-1 - Celcuity, Inc.See more
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer - ASCENT-03 - Gilead SciencesSee more
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy - CAMBRIA-1 - AstraZenecaSee more
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) - MK-2870-012 - Merck Sharp & Dohme LLCSee more
Multiple myeloma
SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM - IRAKLIA - SanofiSee more
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) - Successor-1 - Bristol-Myers SquibbSee more
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide - MonumenTAL-6 - Janssen Research & Development, LLCSee more
Advanced tumors
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002) - MK-7339-002 - AstraZenecaSee more
A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101) - HAMMER - Synthorx, Inc, a Sanofi companySee more
Colorectal cancer
Chemoradiation and Consolidation Chemotherapy With or Without Oxaliplatin for Distal Rectal Cancer and Watch and Wait - CCHOWW - Hospital Alemão Oswaldo CruzSee more
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer - MOUNTAINEER-03 - Seagen Inc.See more
Solid tumors
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002) - MK-7339-002 - AstraZenecaSee more
A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101) - HAMMER - Synthorx, Inc, a Sanofi companySee more
Bladder Cancer
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin - VOLGA - AstraZenecaSee more
Diffuse sclerosis
A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms - VITALISScE™ - Boehringer IngelheimSee more
Endometrial Cancer
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) - MK-2870-005 - GOG FoundationSee more
Graft versus Host Disease
A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease. - ROCKnrol-1 - SanofiSee more
Head and neck cancer
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 - AHEAD-MERIT - BioNTech SESee more
Kidney cancer
A Study of Adjuvant V940 and Pembrolizumab in Renal Cell Carcinoma (V940-004) - INTerpath-004 - Merck Sharp & Dohme LLCSee more
Leukemia
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010) - BELLWAVE-010 - Merck Sharp & Dohme LLCSee more
Liposarcoma
Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma - Brightline-4 - Boehringer IngelheimSee more
Lupus
A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus - TOPAZ-2 - BiogenSee more
Multiple System Atrophy
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy - CYPRESS - Theravance BiopharmaSee more
Myelodysplastic Syndromes
ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions - ELEMENT-MDS - Bristol-Myers SquibbSee more
Nephropathy
Non-Hodgkin Lymphoma
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010) - BELLWAVE-010 - Merck Sharp & Dohme LLCSee more
Prostate cancer
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) - MK-5684-003 - Merck Sharp & Dohme LLCSee more
Pulmonary hypertension
A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients - APD811-301 - United TherapeuticsSee more
Ulcerative colitis
Urothelial cancer
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) - Duravelo-2 - BicycleTx LimitedSee more
